SCHEMBL2050989

SCHEMBL2050989

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OC(=O)Cc5ccccc5)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLA1 P09884 1/20 0.72
▸ CYP46A1 Q9Y6A2 2/20 0.68
▸ OSBP P22059 3/20 0.64
▸ USP2 O75604 2/20 0.64
▸ LMNA P02545 1/20 0.64
▸ ABCB1 P08183 1/20 0.64
▸ RORC P51449 1/20 0.64
▸ OSBP2 Q969R2 1/20 0.64
▸ NPC1 O15118 1/20 0.58
▸ CYP1A2 P05177 1/20 0.57
▸ NR1H3 Q13133 4/20 0.57
▸ PLA2G2A P14555 1/20 0.56
▸ NPC1L1 Q9UHC9 2/20 0.56
▸ EPHA2 P29317 1/20 0.55
▸ GBA1 P04062 2/20 0.55
▸ UGCG Q16739 2/20 0.55
▸ GBA2 Q9HCG7 2/20 0.55
▸ STS P08842 1/20 0.55
▸ GRIN1 Q05586 1/20 0.55
▸ GRIN2A Q12879 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2050990 1.00 POLA1 (0.72) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL23070074 1.00 POLA1 (0.72) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL10936315 1.00 POLA1 (0.72) POLA1CYP46A1OSBPUSP2LMNA
Ammonia Solution, Strong SCHEMBL21817009 0.99 POLA1 (0.71) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL7787257 0.92 POLA1 (0.70) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL21177708 0.92 POLA1 (0.70) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL10707535 0.92 POLA1 (0.70) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL7787254 0.92 POLA1 (0.70) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL29055425 0.92 POLA1 (0.70) POLA1CYP46A1OSBPUSP2LMNA
SCHEMBL5888344 0.92 POLA1 (0.68) POLA1CYP46A1OSBPUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119959397-A Method for simultaneously detecting multiple cholesteric liquid crystal monomers in environmental medium 暨南大学 2025-05-09 — — CN claimed
CN-115461096-A Polymer encapsulated drug particles 吉益医疗公司 2022-12-09 — — CN claimed
EP-4025660-A1 THERMOCHROMIC LIQUID CRYSTAL INKS AND COATINGS Sun Chemical Corporation (US) 2022-07-13 — — EP claimed
WO-2021046004-A1 THERMOCHROMIC LIQUID CRYSTAL INKS AND COATINGS SUN CHEMICAL CORPORATION (US) 2021-03-11 — — WO claimed
CN-112451682-A Conjugates comprising self-degrading groups and methods relating thereto 乐高化学生物科学股份有限公司 2021-03-09 — — CN claimed
CN-111065416-A Hydrophilic linkers and conjugates thereof 芬兰吉利科斯有限公司 2020-04-24 — — CN claimed
WO-2007143173-A2 ATHEROGENIC COMPOSITIONS AND ANIMAL MODELS OF VASCULAR LESIONS THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) 2007-12-13 — — WO claimed
US-4544545-A MEDICAL DIAGNOSIS AND THERAPY TRUSTEES UNIVERSITY OF MASSACHUSETTS (US) 1985-10-01 — — US claimed
US-12605342-B2 Polymer-encapsulated drug particles TONIC MEDICAL, INC. (US) 2026-04-21 — — US disclosed
US-12576037-B2 Polymer-encapsulated drug particles TONIC MEDICAL, INC. (US) 2026-03-17 — — US disclosed
EP-4106828-B1 POLYMER-ENCAPSULATED DRUG PARTICLES TONIC MEDICAL INC (US) 2026-03-11 — — EP disclosed
EP-4678198-A2 POLYMER-ENCAPSULATED DRUG PARTICLES Tonic Medical, Inc. (US) 2026-01-14 — — EP disclosed
US-20250352774-A1 BALLOON CATHETER AND METHODS OF USING THE SAME AIRIVER MEDICAL INC (US) 2025-11-20 — — US disclosed
EP-3745105-B1 TEMPERATURE DETECTION LABEL AND ARTICLE MANAGEMENT DEVICE USING SAME HITACHI LTD (JP) 2025-08-27 — — EP disclosed
CN-1228416-C Material of developing color and indicating temperature for mixed liquid crystal UNIV JINAN (CN) 2005-11-23 — — CN disclosed
CN-1485399-A Material of developing color and indicating temperature for mixed liquid crystal 暨南大学 2004-03-31 — — CN disclosed
US-4544545-A MEDICAL DIAGNOSIS AND THERAPY TRUSTEES UNIVERSITY OF MASSACHUSETTS (US) 1985-10-01 — — US disclosed
US-4140016-A CHOLESTERIC LIQUID CRYSTAL THERMOMETERS, BENZOIC ESTER DERIVATIVES BECTON, DICKINSON AND COMPANY (US) 1979-02-20 — — US disclosed
US-4101207-A Preparation of liquid crystal containing polymeric structure OWENS-ILLINOIS, INC. (US) 1978-07-18 — — US disclosed
US-3935337-A Preparation of liquid crystal containing polymeric structure OWENS-ILLINOIS, INC. (US) 1976-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12576037-B2 Polymer-encapsulated drug particles PHOSPHO1, SGMS1, SGMS2 POLA1 3432/4885CYP46A1 1580/4885OSBP 1530/4885
US-12605342-B2 Polymer-encapsulated drug particles MUC1, SLC10A2, EGFR POLA1 3846/4885CYP46A1 1706/4885OSBP 2135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback